Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small-molecule injectable drugs for the treatment of cancer. The Company has three primary drugs and AI technology programs: AL-101 - Intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinsonâ€™s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P- a vascular disrupting agent (VDA) - in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503- a second generation VDA - for the treatment of liquid tumors with focus on childhood leukemia; OT-101 - an antisense against TGF-b2-for the treatment of various cancers and for the treatment of various viruses, and Artemisinin-a natural derivative from an Asian herb Artemisia Annua.

Employees

Sector

Biotechnology & Medical Research

More about the company

End-of-day quote OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

08-13	Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-02	Oncotelic Therapeutics, Inc. announced that it has received $0.157001 million in funding from Pacific Pier Capital Ii, Llc	CI

Market Cap	10.71M 9.32M 8.8M 7.99M 14.97M 1.03B 15.04M 105M 40.64M 522M 40.21M 39.32M 1.68B	P/E 2024	-3.13x	P/E 2025	0.13x
Enterprise Value	24.53M 21.36M 20.16M 18.32M 34.31M 2.35B 34.47M 241M 93.12M 1.2B 92.14M 90.09M 3.85B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	56.48%	Yield 2024 *	-	Yield 2025	-

08-13	Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-02	Oncotelic Therapeutics, Inc. announced that it has received $0.157001 million in funding from Pacific Pier Capital Ii, Llc	CI
07-22	Oncotelic Therapeutics, Inc. announced that it has received $0.71184 million in funding	CI
07-09	Oncotelic Therapeutics, Inc. announced that it expects to receive $0.71184 million in funding	CI
07-07	Oncotelic Therapeutics, Inc. and Sapu Nano (Us) LLC Advance Joint Clinical Program and Expand European Clinical Sites	CI
06-29	Oncotelic Therapeutics, Inc. and Sapu Nano Announce Peer-Reviewed Validation of Deciparticle Platform Supporting Clinical Development of Sapu003	CI
06-22	Oncotelic Therapeutics, Inc. announced that it has received $0.157001 million in funding from Pacific Pier Capital Ii, Llc	CI
06-18	Oncotelic Therapeutics, Inc. Launches AI-Powered GMP Manufacturing Services Platform At BIO International Convention 2026	CI
06-17	Oncotelic Therapeutics, Inc. And TechForce Robotics, Inc. Advance AI-Powered GMP Manufacturing Services Platform For Revenue-Generating AI And Robotics Manufacturing Services	CI
06-17	TechForce Robotics Advances Phase 2 Deployment Of PUR-E Autonomous Clean Room Support Robot At SAPU Bio OEB-5 Sterile Injectable cGMP Facility	CI
06-08	Oncotelic Therapeutics, Inc. Showcases Pdaoai Capability in Advancing Drug Development	CI
05-14	Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Sapu Nano And Oncotelic Therapeutics, Inc. Announce First Patient Dosed In Phase 1b Trial Of Sapu003, An Intravenous Deciparticle Formulation Of Everolimus	CI

08-03	Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th	AQ
07-23	Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle Technology Supporting the Ongoing Clinical Development of Sapu003	AQ
07-22	Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)	AQ
07-07	Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway	AQ
06-29	Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003	AQ

Mateon Therapeutics, Inc. Stock OTC Markets

Stocks

MATN

US57667K1097

Biotechnology & Medical Research

Valuation: Mateon Therapeutics, Inc.

Latest news: Mateon Therapeutics, Inc.

Press Releases: Mateon Therapeutics, Inc.

Managers and Directors: Mateon Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Vuong Trieu CEO	Chief Executive Officer	61	2019-04-21
Amit Bhupendra Shah DFI	Director of Finance/CFO	59	2019-06-30
Seymour H. Fein CTO	Chief Tech/Sci/R&D Officer	77	2020-01-05

Director	Title	Age	Since
Vuong Trieu CHM	Chairman	61	2019-04-21
Steven King BRD	Director/Board Member	61	2020-05-10
Anthony Maida BRD	Director/Board Member	61	2020-05-10

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MATEON THERAPEUTICS, INC.	-.--%	-.--%	-	-	10.71M
WUXI APPTEC CO., LTD.	-0.31%	+5.79%	+48.93%	+97.53%	70.88B
ARGENX SE	+0.39%	+2.06%	+40.91%	+78.49%	62.49B
INSMED INCORPORATED	-3.21%	-7.27%	-17.73%	+351.98%	26.21B
WUXI BIOLOGICS (CAYMAN) INC.	+0.50%	+7.13%	+29.43%	+15.48%	26.34B
BIONTECH SE	-2.64%	-0.69%	-0.26%	-11.90%	24.13B
GENMAB A/S	+0.71%	+8.03%	+27.22%	-13.18%	20.72B
PHARMAESSENTIA CORPORATION	-1.26%	-7.81%	+169.33%	+302.38%	15.36B
EXELIXIS, INC.	-0.22%	+3.99%	+44.28%	+173.35%	14.46B
SUMMIT THERAPEUTICS INC.	+0.73%	+1.71%	-7.18%	+886.19%	14.25B
Average	-0.53%	+1.65%	+37.22%	+208.92%	30.54B
Weighted average by Cap.	-0.47%	+1.44%	+36.51%	+147.97%

	2024	2025
Net sales	-	-
Net income	-4.52M -3.94M -3.72M -3.38M -6.33M -434M -6.36M -44.46M -17.17M -221M -16.99M -16.62M -710M	249M 217M 205M 186M 349M 23.9B 350M 2.45B 946M 12.15B 936M 916M 39.1B
Net Debt	13M 11.32M 10.69M 9.71M 18.19M 1.25B 18.27M 128M 49.36M 634M 48.84M 47.75M 2.04B	13.82M 12.04M 11.36M 10.32M 19.33M 1.33B 19.42M 136M 52.48M 674M 51.92M 50.77M 2.17B